Drugs / Suvratoxumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07612813 | Jun 2026 → Sep 2027 expected | staphylococcus aureus infection | AstraZeneca | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05331885 | Sep 2022 → Jul 2024 | staphylococcus aureus infection | Aridis Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01769417 Comparator | Jan 2013 → May 2014 | staphylococcus aureus infection | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT02296320 Comparator | Oct 2014 → Oct 2018 | staphylococcus aureus pneumonia | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Suvratoxumab | “AZD7760, a mAb combination of suvratoxumab (labeled as MEDI4893) and AZD7745” NCT07612813 ↗ |
| Known as | MEDI4893 | “AZD7760, a mAb combination of suvratoxumab (labeled as MEDI4893) and AZD7745” NCT07612813 ↗ |
| Action | Inhibit | “specifically binds to and neutralizes alpha-toxin” PMID 27795368 ↗ Dec 2016 |
| Modality | Monoclonal antibody | “human monoclonal antibody” NCT01769417 ↗ |
| Route | Intravenous | “administered as a single IV dose” NCT01769417 ↗ |